Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.

Bordetella pertussis Tdap vaccination adults disease burden underreporting

Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
31 Dec 2024
Historique:
medline: 2 4 2024
pubmed: 2 4 2024
entrez: 2 4 2024
Statut: ppublish

Résumé

Pertussis has several notable consequences, causing economic burden, increased strain on healthcare facilities, and reductions in quality of life. Recent years have seen a trend toward an increase in pertussis cases affecting older children and adults. To boost immunity, and protect vulnerable populations, an enduring approach to vaccination has been proposed, but gaps remain in the evidence surrounding adult vaccination that are needed to inform such a policy. Gaps include: the true incidence of pertussis and its complications in adults; regional variations in disease recognition and reporting; and incidence of severe disease, hospitalizations, and deaths in older adults. Better data on the efficacy/effectiveness of pertussis vaccination in adults, duration of protection, and factors leading to poor vaccine uptake are needed. Addressing the critical evidence gaps will help highlight important areas of unmet need and justify the importance of adult pertussis vaccination to healthcare professionals, policymakers, and payers.

Identifiants

pubmed: 38564339
doi: 10.1080/21645515.2024.2324547
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2324547

Auteurs

Peter Kardos (P)

Group Practice & Center, Allergy, Respiratory and Sleep Medicine, Maingau Hospital of the Red Cross, Frankfurt am Main, Germany.

Jaime Correia de Sousa (J)

Life and Health Sciences Research Institute, School of Medicine, University of Minho School of Medicine, Braga, Portugal.

Ulrich Heininger (U)

Pediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel Switzerland.

Andreas Konstantopoulos (A)

Department of Pediatrics, University of Athens, Athens, Greece.

C Raina MacIntyre (CR)

Kirby Institute, UNSW Medicine, University of New South Wales, Sydney, Australia.

Donald Middleton (D)

Department of Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, USA.

Terry Nolan (T)

Department of Infectious Diseases, University of Melbourne, Melbourne, Australia.

Alberto Papi (A)

Department of Translational Medicine, University of Ferrara, Ferrara, Italy.

Adrian Rendon (A)

Pulmonary/Critical Care Division, Autonomous University of Nuevo León, San Nicolás de los Garza, Mexico.

Albert Rizzo (A)

American Lung Association, Chicago, USA.

Kim Sampson (K)

Immunisation Coalition, Melbourne, Australia.

Alessandro Sette (A)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, USA.

Elizabeth Sobczyk (E)

AMDA - The Society for Post-Acute and Long-Term Care Medicine, Denver, USA.

Tina Tan (T)

Feinberg School of Medicine, Northwestern University, Chicago, USA.

Catherine Weil-Olivier (C)

Department of Pediatrics, University of Paris, Paris, France.

Birgit Weinberger (B)

Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.

Tom Wilkinson (T)

Faculty of Medicine, University of Southampton, Southampton, UK.

Carl Heinz Wirsing von König (CH)

Clinical Microbiology Consultant, Cologne, Germany.

Classifications MeSH